CAP-02-RECHALLENGE

NCT05008016 📎

Regimen

Experimental
camrelizumab + apatinib

Population

Advanced ESCC with prior immune checkpoint inhibitor exposure

Key finding

Confirmed ORR 10.2%, DCR 69.4%, mPFS 4.6 mo, mOS 7.5 mo in post-ICI ESCC; did NOT reach clinically meaningful ORR threshold

Source: PMID 39307038

Timeline